Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909495 | 0.98 | CCR5 (0.53) | CCR5PTGDR2HRH3KCNH2CA12 | |
| SCHEMBL2916843 | 0.93 | CCR5 (0.57) | CCR5PTGDR2HRH3KCNH2 | |
| SCHEMBL2910485 | 0.88 | CCR5 (0.65) | CCR5HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL2917628 | 0.87 | CCR5 (0.64) | CCR5HRH3KCNH2 | |
| SCHEMBL6841896 | 0.83 | DPP4 (0.43) | CCR5PTGDR2HRH3KCNH2 | |
| SCHEMBL2911935 | 0.82 | CCR5 (0.51) | CCR5HRH3KCNH2 | |
| SCHEMBL2909666 | 0.81 | CCR5 (0.60) | CCR5HRH3KCNH2 | |
| SCHEMBL2916232 | 0.81 | CCR5 (0.52) | CCR5PTGDR2HRH3KCNH2 | |
| SCHEMBL3038072 | 0.81 | CCR5 (0.67) | CCR5HRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL2910989 | 0.81 | CCR5 (0.59) | CCR5HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673829-B2 | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, THE PERIPHERAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM, THE PULMONARY SYSTEM, THE GASTROINTESTINAL SYSTEM AND THE ENDOCRINOLOGICAL SYSTEM. | NOVO NORDISK A/S (DK) | 2004-01-06 | — | — | US | disclosed |
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | VTVX HOLDINGS II LLC | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130253-A1 | Novel aminoazetidine,-pyrrolidine and -piperidine derivatives | HRH3, HRH1, HRH2 | CCR5 1186/4885PTGDR2 79/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.